Search Within

Allison Parascondola

Formats
  1. Meeting Abstract (21)
  2. Journal Article (6)
Groups
  1. Bone Marrow Transplant (27)
  2. CTCR Scholars (27)
  3. Center for Hematologic Malignancies (27)
  4. Department of Medicine (27)
  5. Hematologic Malignancies, Division of (27)
  6. Survivorship Research (26)

More Groups

People
  1. Michael Scordo (27)
  2. Gunjan Shah (26)
  3. Miguel-Angel Perales (25)
  4. Roni Shouval (25)
  5. Maria Palomba (24)
  6. Gilles Salles (23)

More People

Years
  1. 2025 (5)
  2. 2024 (3)
  3. 2023 (13)
  4. 2022 (5)
  5. 2021 (1)
Publications
  1. Blood (15)
  2. Bone Marrow Transplantation (2)
  3. Hematological Oncology (2)
  4. Transplantation and Cellular Therapy (2)
  5. Blood Cancer Discovery (1)
  6. Blood Cancer Journal (1)

More Publications

Publishers
  1. American Society of Hematology (15)
  2. Nature Publishing Group (4)
  3. Elsevier Inc. (3)
  4. American Association for Cancer Research (2)
  5. Wiley Blackwell (2)
  6. Ferrata Storti Foundation (1)

Results (27)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T‐cell therapy outcome
    Meeting Abstract

    Imber, B. S.; Silverman, E. A.; Leithner, D.; Hubbeling, H.; Shah, G. L.; Fregonese, B.; Sanin, B. W.; Tomas, A. A.; Parascondola, A.; Saldia, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Severe persistent cytopenias following CAR T-cell therapy in patients with large B-cell lymphoma
    Meeting Abstract

    De Lapuerta, M. C.; Shouval, R.; Tomas, A. A.; Flynn, J. R.; Devlin, S. M.; Batlevi, C. L.; Fein, J. A.; Giralt, S. A.; Lin, R. J.; Nath, K.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Predictors and implications of renal injury in large cell lymphoma patients receiving CD19 CAR T cell therapy
    Meeting Abstract

    Boardman, A. P.; Gutgarts, V.; Flynn, J. R.; Devlin, S. M.; Tomas, A. A.; Fein, J. A.; Slingerland, J.; Parascondola, A.; Lin, R. J.; Scordo, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Population pharmacokinetic model identifies an optimal fludarabine exposure for improved outcomes after CD19-directed CAR T cell therapy for aggressive B-NHL: Analysis from the Cell Therapy Consortium
    Meeting Abstract

    Scordo, M.; Flynn, J. R.; Devlin, S. M.; Gonen, M.; Parascondola, A.; Tomas, A. A.; Shouval, R.; Brower, J.; Porter, D. L.; Schuster, S. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Inflammatory biomarker clusters are predictive of response and toxicity in large B-cell lymphoma treated with CD19 CAR-T cell therapy
    Meeting Abstract

    Raj, S.; Perales, M. A.; Fein, J. A.; Tomas, A. A.; Batlevi, C. L.; De Lapuerta, M. C.; Dahi, P. B.; Danylesko, I.; Fried, S.; Funnell, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Interim analysis of the 2nd chance protocol: A multicenter trial of daratumumab, carfilzomib, lenalidomide, & dexamethasone for relapsed/refractory myeloma with salvage autologous hematopoietic cell transplantation
    Meeting Abstract

    Shah, G. L.; Bal, S.; Rodriguez, C.; Chhabra, S.; Bayer, R. L.; Costa, L. J.; Lambird, J.; Ferrer, C.; Parascondola, A.; Marcello, L.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Daratumumab, carfilzomib, lenalidomide, & dexamethasone for relapsed/refractory myeloma with salvage autologous hematopoietic cell transplant: Interim analysis of the multicenter 2nd chance protocol
    Meeting Abstract

    Shah, G.; Bal, S.; Rodriguez, C.; Chhabra, S.; Bayer, R.; Costa, L.; Lambird, J.; Ferrer, C.; Parascondola, A.; Marcello, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save